April 2026

CARDIOVASCULAR

CLINICAL EVIDENCE SUPPORTS ORAL COMBINATION THERAPY FOR PATIENTS WITH ADVANCED LEIOMYOSARCOMA

Featuring: Seth M. Pollack, MD

Episode Summary

In this episode of Better Edge, Oncologist Seth M. Pollack, MD, discusses the evolving treatment landscape for leiomyosarcoma and highlights clinical trial data recently published in The Lancet Oncology. Dr. Pollack was co-author on the study, which evaluated the combination of cabozantinib, a multitargeted tyrosine kinase inhibitor, with temozolomide in patients with refractory soft tissue sarcomas.

​The conversation covers the biologic mechanisms underpinning this strategy, trial design and outcomes, and how the trial’s findings compare with existing systemic therapies. The discussion also emphasizes the value of referral to specialized sarcoma centers with multidisciplinary expertise and access to subtype specific clinical trials.
Seth M. Pollack, MD, Steven T. Rosen, MD, Professor of Cancer Biology, Professor of Hematology and Oncology

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like